Brokerages expect Evolus Inc (NASDAQ:EOLS) to announce earnings of ($0.37) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Evolus’ earnings. The company is scheduled to issue its next quarterly earnings results on Thursday, August 9th.
According to Zacks, analysts expect that Evolus will report full-year earnings of ($1.65) per share for the current year, with EPS estimates ranging from ($1.72) to ($1.58). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.87) per share, with EPS estimates ranging from ($1.07) to ($0.67). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Evolus.
Evolus (NASDAQ:EOLS) last posted its earnings results on Thursday, May 10th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.06.
Several research firms have commented on EOLS. Cantor Fitzgerald set a $35.00 target price on Evolus and gave the company a “buy” rating in a research report on Wednesday, June 13th. Mizuho increased their target price on Evolus from $16.00 to $33.00 and gave the company a “buy” rating in a research report on Monday, June 11th. SunTrust Banks assumed coverage on Evolus in a research report on Monday, March 5th. They issued a “buy” rating and a $24.00 target price for the company. Zacks Investment Research upgraded Evolus from a “hold” rating to a “buy” rating and set a $8.25 price objective for the company in a research report on Monday, May 7th. Finally, JMP Securities raised their price objective on Evolus from $22.00 to $30.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 29th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $26.05.
In related news, Director Bosun Hau acquired 7,142 shares of the stock in a transaction dated Monday, June 4th. The stock was bought at an average cost of $29.19 per share, for a total transaction of $208,474.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Vikram Malik acquired 8,600 shares of the stock in a transaction dated Thursday, June 14th. The shares were bought at an average price of $28.88 per share, with a total value of $248,368.00. The disclosure for this purchase can be found here. Insiders have bought 27,840 shares of company stock valued at $797,007 over the last 90 days.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EOLS. BlackRock Inc. acquired a new stake in Evolus during the first quarter worth approximately $1,710,000. Citadel Advisors LLC acquired a new stake in Evolus during the first quarter worth approximately $1,554,000. Landscape Capital Management L.L.C. acquired a new stake in Evolus during the first quarter worth approximately $639,000. Northern Trust Corp acquired a new stake in Evolus during the first quarter worth approximately $516,000. Finally, Dean Capital Investments Management LLC acquired a new stake in Evolus during the first quarter worth approximately $314,000. 18.80% of the stock is owned by institutional investors and hedge funds.
Evolus stock traded up $1.00 during trading hours on Friday, hitting $32.94. The stock had a trading volume of 401,788 shares, compared to its average volume of 665,354. The company has a market capitalization of $755.07 million and a PE ratio of -122.00. Evolus has a one year low of $6.75 and a one year high of $39.50.
Evolus, Inc provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.